Edesa Biotech Engages Investors at Global Conferences
Company Announcements

Edesa Biotech Engages Investors at Global Conferences

Edesa Biotech (EDSA) has released an update.

Edesa Biotech, a clinical-stage biopharmaceutical company, has announced its participation in several investor conferences, including events in Toronto, London, and New York. The company, known for developing therapeutics for immuno-inflammatory diseases, is currently advancing their lead drug candidate, EB05, in a Phase 3 study for ARDS, with plans to initiate a Phase 2 study for pulmonary fibrosis. Additionally, Edesa is exploring treatments for vitiligo and chronic Allergic Contact Dermatitis through its dermatology assets.

For further insights into EDSA stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskEdesa Biotech Gains CEO’s Strategic Investment Boost
TheFlyEdesa Biotech founder Par Nijhawan to invest up to $5M in company
TipRanks Canadian Auto-Generated NewsdeskEdesa Biotech to Present at Global Conferences
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App